Enanta Pharmaceuticals Inc - ENTA STOCK NEWS

Enanta Pharmaceuticals (NASDAQ: ENTA) has completed a significant deal with OMERS, a major Canadian pension plan, selling 54.5% of its future royalty payments from AbbVie for $200 million. This agreement pertains to worldwide sales of MAVYRET®/MAVIRET®, effective from July 2023 to June 2032, with total payments capped at 1.42 times the purchase price. Enanta retains 45.5% of the royalties until the cap is reached. The funds from this transaction will support ongoing clinical development in Enanta's virology pipeline. The deal underscores the continuing value of MAVYRET®/MAVIRET® in treating chronic hepatitis C and strengthens Enanta's financial position without diluting shareholder equity.

Enanta Pharmaceuticals (NASDAQ: ENTA) recently presented preclinical data for its antiviral candidates EDP-235 and EDP-323 at the 33rd European Congress of Clinical Microbiology and Infectious Diseases. EDP-235, a 3CL protease inhibitor for SARS-CoV-2, showed superior tissue distribution and cell penetration, which may help address long COVID-19. It is undergoing evaluation in the Phase 2 SPRINT study, with topline data expected in May 2023. EDP-323, an L-protein inhibitor for RSV, demonstrated strong bioavailability and favorable pharmacokinetics, supporting once-daily oral dosing. A Phase 1 study of EDP-323 is ongoing, with results anticipated in Q2 2023. The company highlights ongoing clinical advancements and milestones aimed at developing effective therapies for viral infections.

Enanta Pharmaceuticals (NASDAQ:ENTA) has received Fast Track designation from the FDA for its L-protein inhibitor, EDP-323, aimed at treating respiratory syncytial virus (RSV). This designation highlights EDP-323's potential as an effective oral treatment for RSV, particularly for high-risk populations. In vitro studies show that EDP-323 has sub-nanomolar potency against RSV strains and is expected to be effective as a monotherapy or in combination with other treatments. The Fast Track program allows for expedited development, facilitating more frequent communication with the FDA. A Phase 1 clinical trial assessing EDP-323's safety and pharmacokinetics is underway. Promising preclinical data indicates significant RSV replication reduction and favorable oral bioavailability, suggesting it could become a leading oral antiviral therapy for RSV.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has announced the presentation of data for its leading antiviral candidates EDP-235 and EDP-323 at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen. EDP-235 is a 3CL protease inhibitor aimed at treating COVID-19, while EDP-323 targets respiratory syncytial virus (RSV). Presentations will occur on April 17, with EDP-235's poster focusing on its potential for treating Long COVID, and EDP-323's poster detailing its pharmacokinetics. These developments underscore Enanta's commitment to advancing treatments for viral infections.

Enanta Pharmaceuticals (NASDAQ: ENTA) unveiled promising data on EDP-235 during the 36th International Conference on Antiviral Research in Lyon, France. EDP-235 showcases favorable safety, tolerability, and pharmacokinetics, supporting once-daily dosing without ritonavir. Preclinical studies suggest its potential to reduce COVID-19 transmission and viral rebound. The drug is currently in a Phase 2 trial (SPRINT) for non-hospitalized adults with mild to moderate COVID-19, with data expected in May 2023. Strong preclinical results highlight EDP-235's tissue penetration, and new non-nucleoside inhibitors were identified through high-throughput screening.

Enanta Pharmaceuticals (NASDAQ:ENTA) announced that data for EDP-235, its lead 3CL protease inhibitor for COVID-19, will be presented at the 36th International Conference on Antiviral Research from March 13-17, 2023, in Lyon, France. New clinical data from a Phase 1 study will be showcased, highlighting EDP-235's effectiveness in suppressing viral replication and potentially mitigating viral rebound. Key presentations include an oral presentation on March 15 and several poster presentations on March 14-15. Enanta continues to focus on developing small molecule drugs for viral infections, funded primarily through royalties from hepatitis C products.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company focused on small molecule drugs for viral infections, announced that its CEO, Jay R. Luly, Ph.D., will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 a.m. ET. The live webcast of the event will be available on Enanta's website, with a replay archived for 60 days. Enanta specializes in developing treatments for various viral infections, including respiratory syncytial virus (RSV), SARS-CoV-2, and hepatitis B virus (HBV). Their research is supported by royalties from hepatitis C virus (HCV) collaborations with AbbVie.

Enanta Pharmaceuticals (NASDAQ:ENTA) reported a revenue of $23.6 million for its fiscal first quarter ended December 31, 2022, primarily from royalty revenue linked to AbbVie's MAVYRET/MAVIRET. The company noted a decline in royalty revenue from $27.6 million in the previous year, attributed to lower patient volumes due to COVID-19. R&D expenses decreased to $40.9 million, while G&A expenses rose to $12.7 million. Enanta completed enrollment in the Phase 2 SPRINT study of EDP-235 for COVID-19, with topline data expected in May 2023. Additionally, key data from EDP-323 for RSV is anticipated in Q2 2023.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that Jay R. Luly, Ph.D., President and CEO, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 8:40 a.m. ET. The event will be accessible via a live webcast on Enanta's website, with a replay available for 30 days post-event. Enanta specializes in developing small molecule drugs for viral infections, including candidates for RSV, COVID-19, and hepatitis B virus. Their research is funded by royalties from hepatitis C virus products developed with AbbVie, including the leading treatment regimens MAVYRET® and MAVIRET®.